CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum

References

• Strong MJ. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol. 2017;30:599–607.
   PubMed Web of Science ®Google Scholar
• Zago S, Poletti B, Morelli C, Doretti A, Silani V. Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). Arch Ital Biol. 2011;149:39–56.
   PubMed Web of Science ®Google Scholar
• Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404–23.
   PubMed Web of Science ®Google Scholar
• Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clinic Proceedings. 2018;93:1617.
   PubMed Web of Science ®Google Scholar
• Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001;28:131–8.
   PubMed Web of Science ®Google Scholar
• Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413–7.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Storkebaum E, Vleminckx V, Moons L, Vanopdenbosch L, Scheveneels W, et al. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol Dis. 2004;17:21–8.
   PubMed Web of Science ®Google Scholar
• Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and “sporadic” amyotrophic lateral sclerosis. Nat Genet. 2006;38:411–3.
   PubMed Web of Science ®Google Scholar
• Conforti FL, Sprovieri T, Mazzei R, Ungaro C, La Bella V, Tessitore A, et al. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul Disord. 2008;18:68–70.
   PubMed Web of Science ®Google Scholar
• Fernandez-Santiago R, Hoenig S, Lichtner P, Sperfeld A-D, Sharma M, Berg D, et al. Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol. 2009;256:1337–42.
   PubMed Web of Science ®Google Scholar
• Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, et al. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics 2008;9:33–40.
   PubMed Web of Science ®Google Scholar
• Paubel A, Violette J, Amy M, Praline J, Meininger V, Camu W, et al. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch Neurol. 2008;65:1333–6.
   PubMedGoogle Scholar
• van Es MA, Diekstra FP, Veldink JH, Baas F, Bourque PR, Schelhaas HJ, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 2009;72:287–8.
   PubMed Web of Science ®Google Scholar
• Wu D, Yu W, Kishikawa H, Folkerth RD, Iafrate AJ, Shen Y, et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol. 2007;62:609–17.
   PubMed Web of Science ®Google Scholar
• Crabtree B, Thiyagarajan N, Prior SH, Wilson P, Iyer S, Ferns T, et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry. 2007;46:11810–8.
   PubMed Web of Science ®Google Scholar
• Aparicio-Erriu IM, Prehn J. Molecular mechanisms in amyotrophic lateral sclerosis: the role of angiogenin, a secreted RNase. Front Neurosci. 2012;6:167
   PubMed Web of Science ®Google Scholar
• Subramanian V, Feng Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum Mol Genet. 2007;16:1445–53.
   PubMed Web of Science ®Google Scholar
• Kieran D, Sebastia J, Greenway MJ, King MA, Connaughton D, Concannon CG, et al. Control of motoneuron survival by angiogenin. J Neurosci. 2008;28:14056–61.
   PubMed Web of Science ®Google Scholar
• Skorupa A, King MA, Aparicio IM, Dussmann H, Coughlan K, Breen B, et al. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. J Neurosci. 2012;32:5024–38.
   PubMed Web of Science ®Google Scholar
• Sebastià J, Kieran D, Breen B, King MA, Netteland DF, Joyce D, et al. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 2009;16:1238.
   PubMed Web of Science ®Google Scholar
• Adams SA, Subramanian V. The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis. 1999;3:189–99.
   PubMedGoogle Scholar
• Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JHM, et al. Elevated serum angiogenin levels in ALS. Neurology. 2006;67:1833–6.
   PubMed Web of Science ®Google Scholar
• van Es MA, Veldink JH, Schelhaas HJ, Bloem BR, Sodaar P, van Nuenen BFL, et al. Serum angiogenin levels are elevated in ALS, but not Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85:1439–40.
   PubMed Web of Science ®Google Scholar
• McLaughlin RL, Phukan J, McCormack W, Lynch DS, Greenway M, Cronin S, et al. Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosis. PLoS One. 2010;5:e15402.
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Cerebrospinal fluid angiogenin level in patients with amyotrophic lateral sclerosis. Acta Clin Croat. 2008;47:77–9.
   PubMed Web of Science ®Google Scholar
• Moreau C, Gosset P, Brunaud-Danel V, Lassalle P, Degonne B, Destee A, et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph Lateral Scler. 2009;10:175–81.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18:153–74.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914.
   PubMed Web of Science ®Google Scholar
• Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90.
   PubMed Web of Science ®Google Scholar
• Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang Y-J, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:pii:eaai7866.
   Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, Muller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79:152–8.
   PubMed Web of Science ®Google Scholar
• Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;90:157–64.
   PubMed Web of Science ®Google Scholar
• Gendron TF, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, et al. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82:139.
   PubMed Web of Science ®Google Scholar
• Nygren I, Larsson A, Johansson A, Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport. 2002;13:2199–201.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhou S, Cai H, Gong Z, Zang D. VEGF levels in CSF and serum in mild ALS patients. J Neurol Sci. 2014;346:216–20.
   PubMed Web of Science ®Google Scholar
• Stanga S, Brambilla L, Tasiaux B, Dang AH, Ivanoiu A, Octave J-N, et al. A role for gdnf and soluble app as biomarkers of amyotrophic lateral sclerosis pathophysiology. Front Neurol. 2018;9:384.
   PubMed Web of Science ®Google Scholar
• Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423–34.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neur Neurosur Psychiatry. 2018;90:4–10.
   PubMed Web of Science ®Google Scholar